IPSC (Century Therapeutics) Insider Ownership: 4.35 % (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPSC Century Therapeutics Inc IPSC
46 GF Score
Price $2.11
GF Value $39.29
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Century Therapeutics Insider Ownership?

Century Therapeutics IPSC -2.76% 46 Insider Ownership is 4.35 % as of Jul. 26, 2026. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $39.29 (Possible Value Trap). The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Century Therapeutics's insider ownership is 4.35%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Century Therapeutics's Institutional Ownership is 78.88%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Century Therapeutics's Float Percentage Of Total Shares Outstanding is 99.26%.

Century Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Century Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Century Therapeutics Insider Ownership Chart

Century Therapeutics Historical Data

The historical data trend for Century Therapeutics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 5.45 5.45 7.28 8.16 8.16 8.07 8.18 4.44 4.36 4.35
IPSC
46GF Score
Century Therapeutics Inc IPSC
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Century Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 4.35 % mean?
Century Therapeutics (IPSC) has a Insider Ownership of 4.35 % as of Jul. 26, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Century Therapeutics and its competitors.
Is Century Therapeutics' Insider Ownership too high?
Century Therapeutics' current Insider Ownership is 4.35 %. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Insider Ownership compare to PBYI and BNTC?
Century Therapeutics' Insider Ownership of 4.35 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Century Therapeutics and its competitors. Century Therapeutics's current Insider Ownership is 4.35 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $39.29, compared to a current price of $2.11 — trading 94.6% below its estimated fair value. The current Insider Ownership is 4.35 %. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Insider Ownership is 4.35 % as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Century Therapeutics (IPSC) Overvalued in 2026?

Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued. The current stock price of $2.11 is trading 94.6% below its estimated GF Value™ of $39.29. GuruFocus considers Century Therapeutics to be Possible Value Trap.

Key valuation signals for IPSC:

  • Insider Ownership: 4.35 %
  • GF Value™: $39.29 vs. price of $2.11 (94.6% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Century Therapeutics Business Description

Address 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score

Get the complete analysis for IPSC

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.11
Price
$39.29
GF Value